Stephens Inc. AR Has $9.21 Million Position in Pfizer Inc. (NYSE:PFE)

Stephens Inc. AR grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.8% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 363,368 shares of the biopharmaceutical company's stock after buying an additional 16,489 shares during the period. Stephens Inc. AR's holdings in Pfizer were worth $9,208,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Bessemer Group Inc. raised its position in Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after purchasing an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK raised its position in Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after purchasing an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Pfizer during the first quarter worth approximately $8,283,000. Alta Advisers Ltd increased its holdings in shares of Pfizer by 69.6% during the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after buying an additional 13,100 shares in the last quarter. Finally, WCM Investment Management LLC increased its holdings in shares of Pfizer by 8.7% during the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after buying an additional 10,051 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Down 0.5%

PFE opened at $25.65 on Monday. The firm's fifty day moving average is $23.89 and its two-hundred day moving average is $24.78. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a market cap of $145.83 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the business posted $0.82 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. Pfizer's payout ratio is 124.64%.

Analysts Set New Price Targets

Several analysts have recently weighed in on PFE shares. TD Cowen dropped their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. UBS Group increased their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Citigroup increased their price target on shares of Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Morgan Stanley increased their price target on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. Finally, Wolfe Research increased their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.